Fig. 3From: The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)Disease outcome according to Recurrence Score group: (a) freedom from distant recurrence, and (b) disease-free survivalBack to article page